Exact Mass: 556.2686
Exact Mass Matches: 556.2686
Found 500 metabolites which its exact mass value is equals to given mass value 556.2686
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
RD4-2174
Ingenol 3,20-dibenzoate is a benzoate ester. Ingenol 3,20-dibenzoate is a potent protein kinase C (PKC) isoform-selective agonist. Ingenol 3,20-dibenzoate induces selective translocation of nPKC-delta, -epsilon, and -theta and PKC-mu from the cytosolic fraction to the particulate fraction and induces morphologically typical apoptosis through de novo synthesis of macromolecules. Ingenol 3,20-dibenzoate increases the IFN-γ production and degranulation by NK cells, especially when NK cells are stimulated by NSCLC cells[1][2]. Ingenol 3,20-dibenzoate is a potent protein kinase C (PKC) isoform-selective agonist. Ingenol 3,20-dibenzoate induces selective translocation of nPKC-delta, -epsilon, and -theta and PKC-mu from the cytosolic fraction to the particulate fraction and induces morphologically typical apoptosis through de novo synthesis of macromolecules. Ingenol 3,20-dibenzoate increases the IFN-γ production and degranulation by NK cells, especially when NK cells are stimulated by NSCLC cells[1][2].
2-O-[6-O-Octanoyl-alpha-D-glucopyranosyl-(1->6)-alpha-D-glucopyranosyl]-D-glycerate
Dipiperamide C
Dipiperamide C is found in herbs and spices. Dipiperamide C is an alkaloid from white pepper, Piper nigrum. Alkaloid from white pepper, Piper nigrum. Dipiperamide C is found in herbs and spices.
Dronedarone
C - Cardiovascular system > C01 - Cardiac therapy > C01B - Antiarrhythmics, class i and iii > C01BD - Antiarrhythmics, class iii C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents Dronedarone (SR 33589), a derivative of amiodarone (HY-14187), is a class III antiarrhythmic agent for the study of atrial fibrillation (AF) and atrial flutter. Dronedarone is a potent blocker of multiple ion currents, including potassium current, sodium current, and L-type calcium current, and exhibits antiadrenergic effects by noncompetitive binding to β-adrenergic receptors. Dronedarone is a substrate for and a moderate inhibitor of CYP3A4[1].
Omadacycline
Pexmetinib
PA(2:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))
PA(2:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Resolvin D5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/2:0)
PA(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/2:0), in particular, consists of one chain of one Resolvin D5 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(2:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))
PA(2:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Protectin DX at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/2:0)
PA(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/2:0), in particular, consists of one chain of one Protectin DX at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
Iryantherin G
Iryantherin H
Dronedarone
C - Cardiovascular system > C01 - Cardiac therapy > C01B - Antiarrhythmics, class i and iii > C01BD - Antiarrhythmics, class iii C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents CONFIDENCE standard compound; INTERNAL_ID 2181 CONFIDENCE standard compound; EAWAG_UCHEM_ID 2855 INTERNAL_ID 2181; CONFIDENCE standard compound Dronedarone (SR 33589), a derivative of amiodarone (HY-14187), is a class III antiarrhythmic agent for the study of atrial fibrillation (AF) and atrial flutter. Dronedarone is a potent blocker of multiple ion currents, including potassium current, sodium current, and L-type calcium current, and exhibits antiadrenergic effects by noncompetitive binding to β-adrenergic receptors. Dronedarone is a substrate for and a moderate inhibitor of CYP3A4[1].
6,9-Dihydroxymegastigm-7-en-3-one 9-O-beta-D-glucopyranoside tetraacetate
5alpha,13alpha,15beta-trihydroxy-16beta-methoxyl-1alpha,6alpha,7beta-triacetoxy-12-oxocassane-14,16-epoxy|neocaesalpin AE
methyl-2-hydroxy-3beta-isobutyroxy-1-oxomeliac-8(30)-enate
6beta-acetoxy-7beta-hydroxy-8,13-epoxy-labd-14-en-11-one-1alpha-O-beta-glucopyranoside|forskoditerpenoside C
Asp Phe Ile Tyr
Asp Phe Leu Tyr
Asp Phe Tyr Ile
Asp Phe Tyr Leu
Asp Ile Phe Tyr
Asp Ile Tyr Phe
Asp Leu Phe Tyr
Asp Leu Tyr Phe
Asp Tyr Phe Ile
Asp Tyr Phe Leu
Asp Tyr Ile Phe
Asp Tyr Leu Phe
Glu Phe Val Tyr
Glu Phe Tyr Val
Glu Val Phe Tyr
Glu Val Tyr Phe
Glu Tyr Phe Val
Glu Tyr Val Phe
Phe Asp Ile Tyr
Phe Asp Leu Tyr
Phe Asp Tyr Ile
Phe Asp Tyr Leu
Phe Glu Val Tyr
Phe Glu Tyr Val
Phe Phe Phe Pro
Phe Phe Ile Met
Phe Phe Leu Met
Phe Phe Met Ile
Phe Phe Met Leu
Phe Phe Pro Phe
Phe Ile Asp Tyr
Phe Ile Phe Met
Phe Ile Met Phe
Phe Ile Tyr Asp
Phe Leu Asp Tyr
Phe Leu Phe Met
Phe Leu Met Phe
Phe Leu Tyr Asp
Phe Met Phe Ile
Phe Met Phe Leu
Phe Met Ile Phe
Phe Met Leu Phe
Phe Met Pro Tyr
Phe Met Tyr Pro
Phe Pro Phe Phe
Phe Pro Met Tyr
Phe Pro Tyr Met
Phe Val Glu Tyr
Phe Val Tyr Glu
Phe Tyr Asp Ile
Phe Tyr Asp Leu
Phe Tyr Glu Val
Phe Tyr Ile Asp
Phe Tyr Leu Asp
Phe Tyr Met Pro
Phe Tyr Pro Met
Phe Tyr Val Glu
His His Thr Tyr
His His Tyr Thr
His Lys Ser Trp
His Lys Trp Ser
His Met Asn Arg
His Met Arg Asn
His Asn Met Arg
His Asn Arg Met
His Asn Thr Trp
His Asn Trp Thr
His Gln Ser Trp
His Gln Trp Ser
His Arg Met Asn
His Arg Asn Met
His Ser Lys Trp
His Ser Gln Trp
His Ser Trp Lys
His Ser Trp Gln
His Thr His Tyr
His Thr Asn Trp
His Thr Trp Asn
His Thr Tyr His
His Trp Lys Ser
His Trp Asn Thr
His Trp Gln Ser
His Trp Ser Lys
His Trp Ser Gln
His Trp Thr Asn
His Tyr His Thr
His Tyr Thr His
Ile Asp Phe Tyr
Ile Asp Tyr Phe
Ile Phe Asp Tyr
Ile Phe Phe Met
Ile Phe Met Phe
Ile Phe Tyr Asp
Ile Met Phe Phe
Ile Met Met Tyr
Ile Met Tyr Met
Ile Val Tyr Tyr
Ile Tyr Asp Phe
Ile Tyr Phe Asp
Ile Tyr Met Met
Ile Tyr Val Tyr
Ile Tyr Tyr Val
Lys His Ser Trp
Lys His Trp Ser
Lys Ser His Trp
Lys Ser Trp His
Lys Trp His Ser
Lys Trp Ser His
Leu Asp Phe Tyr
Leu Asp Tyr Phe
Leu Phe Asp Tyr
Leu Phe Phe Met
Leu Phe Met Phe
Leu Phe Tyr Asp
Leu Met Phe Phe
Leu Met Met Tyr
Leu Met Tyr Met
Leu Val Tyr Tyr
Leu Tyr Asp Phe
Leu Tyr Phe Asp
Leu Tyr Met Met
Leu Tyr Val Tyr
Leu Tyr Tyr Val
Met Phe Phe Ile
Met Phe Phe Leu
Met Phe Ile Phe
Met Phe Leu Phe
Met Phe Pro Tyr
Met Phe Tyr Pro
Met His Asn Arg
Met His Arg Asn
Met Ile Phe Phe
Met Ile Met Tyr
Met Ile Tyr Met
Met Leu Phe Phe
Met Leu Met Tyr
Met Leu Tyr Met
Met Met Ile Tyr
Met Met Leu Tyr
Met Met Tyr Ile
Met Met Tyr Leu
Met Asn His Arg
Met Asn Arg His
Met Pro Phe Tyr
Met Pro Tyr Phe
Met Arg His Asn
Met Arg Asn His
Met Tyr Phe Pro
Met Tyr Ile Met
Met Tyr Leu Met
Met Tyr Met Ile
Met Tyr Met Leu
Met Tyr Pro Phe
Asn His Met Arg
Asn His Arg Met
Asn His Thr Trp
Asn His Trp Thr
Asn Met His Arg
Asn Met Arg His
Asn Arg His Met
Asn Arg Met His
Asn Thr His Trp
Asn Thr Trp His
Asn Trp His Thr
Asn Trp Thr His
Pro Phe Phe Phe
Pro Phe Met Tyr
Pro Phe Tyr Met
Pro Met Phe Tyr
Pro Met Tyr Phe
Pro Tyr Phe Met
Pro Tyr Met Phe
Gln His Ser Trp
Gln His Trp Ser
Gln Ser His Trp
Gln Ser Trp His
Gln Trp His Ser
Gln Trp Ser His
Arg His Met Asn
Arg His Asn Met
Arg Met His Asn
Arg Met Asn His
Arg Asn His Met
Arg Asn Met His
Ser His Lys Trp
Ser His Gln Trp
Ser His Trp Lys
Ser His Trp Gln
Ser Lys His Trp
Ser Lys Trp His
Ser Gln His Trp
Ser Gln Trp His
Ser Trp His Lys
Ser Trp His Gln
Ser Trp Lys His
Ser Trp Gln His
Thr His His Tyr
Thr His Asn Trp
Thr His Trp Asn
Thr His Tyr His
Thr Asn His Trp
Thr Asn Trp His
Thr Trp His Asn
Thr Trp Asn His
Thr Tyr His His
Val Glu Phe Tyr
Val Glu Tyr Phe
Val Phe Glu Tyr
Val Phe Tyr Glu
Val Ile Tyr Tyr
Val Leu Tyr Tyr
Val Tyr Glu Phe
Val Tyr Phe Glu
Val Tyr Ile Tyr
Val Tyr Leu Tyr
Val Tyr Tyr Ile
Val Tyr Tyr Leu
Trp His Lys Ser
Trp His Asn Thr
Trp His Gln Ser
Trp His Ser Lys
Trp His Ser Gln
Trp His Thr Asn
Trp Lys His Ser
Trp Lys Ser His
Trp Asn His Thr
Trp Asn Thr His
Trp Gln His Ser
Trp Gln Ser His
Trp Ser His Lys
Trp Ser His Gln
Trp Ser Lys His
Trp Ser Gln His
Trp Thr His Asn
Trp Thr Asn His
Tyr Asp Phe Ile
Tyr Asp Phe Leu
Tyr Asp Ile Phe
Tyr Asp Leu Phe
Tyr Glu Phe Val
Tyr Glu Val Phe
Tyr Phe Asp Ile
Tyr Phe Asp Leu
Tyr Phe Glu Val
Tyr Phe Ile Asp
Tyr Phe Leu Asp
Tyr Phe Met Pro
Tyr Phe Pro Met
Tyr Phe Val Glu
Tyr His His Thr
Tyr His Thr His
Tyr Ile Asp Phe
Tyr Ile Phe Asp
Tyr Ile Met Met
Tyr Ile Val Tyr
Tyr Ile Tyr Val
Tyr Leu Asp Phe
Tyr Leu Phe Asp
Tyr Leu Met Met
Tyr Leu Val Tyr
Tyr Leu Tyr Val
Tyr Met Phe Pro
Tyr Met Ile Met
Tyr Met Leu Met
Tyr Met Met Ile
Tyr Met Met Leu
Tyr Met Pro Phe
Tyr Pro Phe Met
Tyr Pro Met Phe
Tyr Thr His His
Tyr Val Glu Phe
Tyr Val Phe Glu
Tyr Val Ile Tyr
Tyr Val Leu Tyr
Tyr Val Tyr Ile
Tyr Val Tyr Leu
Tyr Tyr Ile Val
Tyr Tyr Leu Val
Tyr Tyr Val Ile
Tyr Tyr Val Leu
PG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)
Dipiperamide C
4-methoxyphenyl 2,4,6-tri-o-benzyl-beta-d-galactopyranoside
9,9-Dimethyl-N,N-bis(3-methylphenyl)-N,N-diphenyl-9H-fluorene-2,7-diamine
4-Methoxyphenyl 2,3,6-Tri-O-benzyl-beta-D-galactopyranoside
Omadacycline
J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01A - Tetracyclines > J01AA - Tetracyclines C254 - Anti-Infective Agent > C258 - Antibiotic
1H-1-Benzazepine-1-acetic acid, 3-(((1-((2R)-2-carboxy-4-(1-naphthalenyl)butyl)cyclopentyl)carbonyl)amino)-2,3,4,5-tetrahydro-2-oxo-, (3S)-
Pexmetinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor
Forskoditerpenoside C
A diterpene glycoside that is labd-14-en-11-one substituted by beta-acetoxy group at position 6, an epoxy group between positions 8 and 13, a beta-hydroxy group at position 7 and a beta-D-glucopyranosyloxy group at position 1 (the 1alpha stereoisomer). Isolated from the whole plant of Coleus forskohlii, it shows relaxative effects on isolated guinea pig tracheal spirals in vitro.
N-(2-Morpholin-4-YL-1-morpholin-4-ylmethyl-ethyl)-3-nitro-5-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-benzamide
(4S,4aS,5aR,12aR)-2-carbamoyl-7-(dimethylamino)-4-(dimethylazaniumyl)-9-[(2,2-dimethylpropylamino)methyl]-10,11,12a-trihydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracen-1-olate
2-[(4-Acetylamino-phenyl)-(2-benzotriazol-1-yl-acetyl)-amino]-2-(4-methoxy-phenyl)-N-(tetrahydro-furan-2-ylmethyl)-acetamide
4-[(1R)-1-phenoxyethyl]-5-[5-[(1R)-1-phenoxyethyl]-3-(phenylmethyl)-4-triazolyl]-1-(phenylmethyl)triazole
N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4,4,4-trifluorobutanamide
(1R)-N-(2-fluorophenyl)-1-(hydroxymethyl)-7-methoxy-2-(1-oxo-2-phenylethyl)-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
[(1R)-2-[(3,5-dimethoxyphenyl)methyl]-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]-(3-pyridinyl)methanone
4-[3-[(3S)-2-[(S)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-6-(piperidine-1-carbonyl)-1,3-dihydropyrrolo[3,4-c]pyridin-4-yl]phenyl]benzonitrile
1-[[(2R,3S)-8-(3-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-(1-naphthalenyl)urea
3-[3-[(3R)-2-[(R)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-6-(piperidine-1-carbonyl)-1,3-dihydropyrrolo[3,4-c]pyridin-4-yl]phenyl]benzonitrile
4-[3-[(3R)-2-[(R)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-6-[oxo(1-piperidinyl)methyl]-1,3-dihydropyrrolo[3,4-c]pyridin-4-yl]phenyl]benzonitrile
N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4,4,4-trifluorobutanamide
3-[3-[(3S)-2-[(S)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-6-[oxo(1-piperidinyl)methyl]-1,3-dihydropyrrolo[3,4-c]pyridin-4-yl]phenyl]benzonitrile
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-(1-methyl-3-indolyl)acetamide
N-[(2R,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4,4,4-trifluorobutanamide
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-(1-methyl-3-indolyl)acetamide
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-(1-methyl-3-indolyl)acetamide
N-[(2R,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4,4,4-trifluorobutanamide
N-[(2R,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4,4,4-trifluorobutanamide
N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-(1-methyl-3-indolyl)acetamide
N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4,4,4-trifluorobutanamide
(1S)-N-(2-fluorophenyl)-1-(hydroxymethyl)-7-methoxy-2-(1-oxo-2-phenylethyl)-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
(2R)-3-hydroxy-2-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(octanoyloxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropanoic acid
[3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate
[2-hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] (Z)-pentadec-9-enoate
[1-Propanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] pentanoate
[1-Acetyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] hexanoate
[2-Butanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropyl] butanoate
(2R)-3-hydroxy-2-{[6-O-(6-O-octanoyl-alpha-D-glucopyranosyl)-alpha-D-glucopyranosyl]oxy}propanoic acid
1-(1Z-hexadecenyl)-glycero-3-phospho-(1-myo-inositol)
1-(9Z-pentadecenoyl)-glycero-3-phospho-(1-myo-inositol)
(3as,5ar,9r,10as)-9-(benzoyloxy)-8-[(benzoyloxy)methyl]-1-isopropyl-5a-methyl-6-oxo-2h,3h,4h,5h,9h,10h,10ah-cyclohepta[e]indene-3a-carboxylic acid
(1s,2r,4r,5r,9r,10r,13r,14r,15s,17r)-9-(furan-3-yl)-15-(2-methoxy-2-oxoethyl)-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.0²,⁴.0⁴,¹³.0⁵,¹⁰]octadecan-17-yl 2-methylpropanoate
6-(furan-3-yl)-16-(1-hydroxy-2-methoxy-2-oxoethyl)-1,5,15,15-tetramethyl-8,17-dioxo-7-oxatetracyclo[11.3.1.0²,¹¹.0⁵,¹⁰]heptadec-11-en-14-yl 2-methylpropanoate
17-ethyl-6,21-dihydroxy-19-[1-(1h-indol-3-yl)ethyl]-7,9,16-trimethyl-15-oxa-20-azatetracyclo[11.8.0.0¹,¹⁸.0¹⁴,¹⁶]henicosa-3,7,11,20-tetraene-2,5-dione
(1s,3z,6r,7z,9s,11z,13r,14s,16r,17s,18r,19s)-17-ethyl-6,21-dihydroxy-19-[(1r)-1-(1h-indol-3-yl)ethyl]-7,9,16-trimethyl-15-oxa-20-azatetracyclo[11.8.0.0¹,¹⁸.0¹⁴,¹⁶]henicosa-3,7,11,20-tetraene-2,5-dione
(1r,5r,6r,13r,14s,16s)-6-(furan-3-yl)-13-hydroxy-16-(2-methoxy-2-oxoethyl)-1,5,15,15-tetramethyl-8,17-dioxo-7-oxatetracyclo[11.3.1.0²,¹¹.0⁵,¹⁰]heptadec-11-en-14-yl 2-methylpropanoate
2alpha-benzoyloxy-9alpha,10beta-diacetoxy-1beta,5alpha,13alpha-trihydroxy-4(20),11-taxadiene
{"Ingredient_id": "HBIN005279","Ingredient_name": "2alpha-benzoyloxy-9alpha,10beta-diacetoxy-1beta,5alpha,13alpha-trihydroxy-4(20),11-taxadiene","Alias": "2\u03b1-benzoyloxy-9\u03b1,10\u03b2-diacetoxy-1\u03b2,5\u03b1,13\u03b1-trihydroxy-4(20),11-taxadiene","Ingredient_formula": "C31H40O9","Ingredient_Smile": "CC1=C2C(C(C3(CCC(C(=C)C3C(C(C2(C)C)(CC1O)O)OC(=O)C4=CC=CC=C4)O)C)OC(=O)C)OC(=O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "25197;2255","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
artocommunol cb
{"Ingredient_id": "HBIN016981","Ingredient_name": "artocommunol cb","Alias": "NA","Ingredient_formula": "C35H40O6","Ingredient_Smile": "CC(=CCCC(=CCC1=C(OC2=C3C=CC(OC3=C(C(=C2C1=O)O)CC=C(C)C)(C)C)C4=C(C=C(C=C4)O)O)C)C","Ingredient_weight": "556.7 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1811","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "639645","DrugBank_id": "NA"}